Chairs: Prof. Dr Raquel Duarte (Porto, Portugal), Prof. Dr Christoph Lange (Borstel, Germany)
Speaker: Prof. Dr Stefan Kaufmann (Berlin, Germany)

Discussants: Dr Andre Swanepoel (Cape Town, South Africa), Dr Zoyia Hassan (Sindh, Pakistan)

Fees: Free for ERS members and non-members
Find out more about becoming a member

Overview

The development of an effective tuberculosis (TB) vaccine is crucial for global health. This webinar addresses the urgent need to understand the current landscape of TB vaccine research, ongoing clinical trials, and potential timelines for vaccine rollout. It's important to cover this topic to keep healthcare professionals and researchers informed about the latest advancements and challenges in TB vaccine development.

Topics:

• Current landscape of TB vaccine research
• Ongoing clinical trials and their progress
• Efficacy challenges in TB vaccine development
• Timeline for potential vaccine rollout
• Impact of new TB vaccines on global health strategies

Format and structure

1. Opening and Introduction (8 minutes)

• Welcome and speaker introduction
• Opening quiz on TB basics
• Overview of TB epidemiology and vaccine need
• Webinar objectives and structure

2. Current Landscape of TB Vaccine Research (12 minutes)

• Interactive map of global vaccine candidates
• Live word cloud on types of TB vaccines
• Key research institutions and collaborations
• Pop-up quiz on vaccine types and mechanisms
• Q&A and discussion

3. Ongoing Clinical Trials: A Deep Dive (15 minutes)

• Case studies of notable trials
• Real-time updates on preliminary results
• Audience challenge on trial outcomes
• Interactive quiz on clinical trial components
• Expert commentary and audience questions

4. Overcoming Hurdles: Efficacy Challenges and Rollout Timeline (15 minutes)

• Expert presentation on key challenges
• Interactive poll on ranking challenges
• Discussion of poll results and expert insights
• Interactive timeline on vaccine availability
• True/False quiz on TB vaccine development misconceptions

5. Future Prospects and Global Health Impact (5 minutes)

• Visualisation of potential global impact
• Quick-fire round on integration with TB strategies
• Multiple-choice challenge on impact scenarios

6. Q&A and Closing (5 minutes)

• Audience questions and expert answers
• Closing quiz and webinar wrap-up

Learning outcomes

Following this webinar, participants will be able to:

• Describe the current state of TB vaccine research and development
• Analyse the progress and challenges of ongoing clinical trials
• Evaluate the efficacy hurdles in TB vaccine development
• Estimate potential timelines for TB vaccine rollout
• Assess the potential impact of new TB vaccines on global health strategies

CME credit

An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.

What is a webinar?

A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.

All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.

Login guidelines

More information will be communicated in due course.

• Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.
• Check Central European Summer Time.
• To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.
• Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.

About UNITE4TB

UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active tuberculosis (TB) treatment regimens for drug-resistant and drug-sensitive TB. For more information, visit the consortium website: www.unite4TB.org

Funding

The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: www.imi.europa.eu

Disclaimer

This communication reflects the author's view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.